AstraZeneca, a leading U.K. pharmaceutical company, has announced plans to invest $50 billion in the United States. This move comes amidst the ongoing trade tensions between the U.S. and its trading partners, with President Trump threatening tariffs on imported drugs. The investment is part of a broader trend in the pharmaceutical industry, where companies are actively seeking to increase their presence and production capacity in the U.S. market. This strategy is likely aimed at appeasing the Trump administration and avoiding potential trade barriers or tariffs on imported drugs. The $50 billion investment by AstraZeneca is expected to be used for various purposes, including the expansion of research and development facilities, manufacturing operations, and the creation of new jobs. The company's move is seen as a strategic response to the changing political and economic landscape in the U.S., as the industry aims to secure its position and maintain access to the lucrative American market.
Jul 22, 2025 → Aug 9, 2025
The article discusses the tariff drama between Switzerland and the United States. Initially, on July 4th, Switzerland's top ministers believed they had secured a deal to avoid punitive tariffs from former US President Donald Trump.…
Read original at Bloomberg →3 updates from 2 sources over 3 weeks.
The article discusses the tariff drama between Switzerland and the United States. Initially, on July 4th, Switzerland's top ministers believed they had secured a deal to avoid punitive tariffs from former US President…
Read original at Bloomberg →The Trump administration has imposed a 15% tariff on pharmaceutical products manufactured in Europe, posing a significant financial burden on drugmakers. This move is expected to cost the industry billions of dollars,…
Read original at NYT →AstraZeneca, a leading U.K. pharmaceutical company, has announced plans to invest $50 billion in the United States. This move comes amidst the ongoing trade tensions between the U.S. and its trading partners, with…
Read original at NYT →What this story stands on. Tier 0 is a primary record or the subject's own words; higher tiers must be attributed, never stated as bare fact.
The article discusses the tariff drama between Switzerland and the United States. Initially, on July 4th, Switzerland's top ministers believed they had secured a deal to avoid punitive tariffs from former US President Donald Trump.…
View source →The Trump administration has imposed a 15% tariff on pharmaceutical products manufactured in Europe, posing a significant financial burden on drugmakers. This move is expected to cost the industry billions of dollars, potentially leading…
View source →AstraZeneca, a leading U.K. pharmaceutical company, has announced plans to invest $50 billion in the United States. This move comes amidst the ongoing trade tensions between the U.S. and its trading partners, with President Trump…
View source →Tier key: T0 = Primary source · T1 = Wire · T2 = Outlet report · T3 = Commentary
Long-running fight over Trump-backed maps takes another turn as absentee voting is already under way in Missouri. This blog is now closed. Sign up for US Breaking News emails Xi…
This new task force is Trump's latest response to the debate over AI safety.
The Trump administration’s decision to revoke the visa of a Peruvian judge who sided with a Chinese company in a port dispute puts a new spotlight on the growing US-China rivalry…
As Bosnians vote in an election this weekend, the country is embracing the US president’s family and friends.
On Equity, we discussed the Trump administration's attempts to rebrand AI.
Donald Trump and Xi Jinping discuss Taiwan arms sales every time they get together but the American stance on the self-ruled island remains unchanged following the Chinese…
